DCT Japan, Specialists in DCT, Celebrates its Third Anniversary ～Achievements in Decentralized clinical trials (DCT) support in Japan and overseas～

2025/02/27
お知らせ
 DCT Japan Inc. (Head Office: Chuo-ku, Tokyo; President: Shinsuke Muto; hereinafter “DCT Japan”) was established in February 2022 as Japan's first company specializing in Decentralized Clinical Trials (DCT) and has just celebrated its third anniversary. As we express our sincere gratitude to all of you for your patronage and support, we would like to report on our achievements to date and introduce our future outlook.
 
 DCT is a method that allows patients to participate in clinical trials with less or no visits to the clinical trial site by utilizing online medical care, home nursing, and IoT technology. DCT has been actively introduced mainly in Europe and the United States as an innovative trial format that realizes patient centricity by reducing the burden on patients and expanding their options for participation in clinical trials, and its use in Japan is increasing as a result of the spread of COVID-19.
 In addition, with drug lag and drug loss becoming serious issues, DCT offers new possibilities to solve these challenges. It enables the rapid recruitment and enrollment of patients from a wide range of areas and is attracting attention as a key method for establishing an international standard for implementing clinical trials.
 
History of DCT Japan
 Since its establishment, with the aim to promote and implement DCT in Japan, DCT Japan has been creating an environment that makes it easier for patients to participate in clinical trials and has been involved in many projects in cooperation with pharmaceutical companies and contract research organizations (CROs). We provide comprehensive DCT solutions from trial planning to implementation, focusing on home nursing, online medical care, patient recruitment, and satellite site network construction.
Below are some of the strengths and achievements we have accumulated.
 
 
【Strengths】
  • Provision of one-stop DCT solutions from trial planning to implementation. By being involved in projects from the planning stage, we can provide optimal designs, including consultation on the use of the latest DCT solutions.
  • Among DCT solutions, we have strengths in recruiting patients through our network of medical sites and in designing and operating flexible visits that do not rely on patients visiting a site. For flexible visits, we propose optimal designs tailored to each project; we leverage home nursing through our nationwide network of registered nurses, satellite site networks for medical procedures and examinations, and the development of online medical treatment solutions through our group company, Integrity Healthcare Co., Ltd.
  • Expert consultants and project managers with extensive experience and knowledge in clinical trials, especially in DCT, provide precise support for projects.
  • An established team structure and global DCT network able to provide DCT solutions not only in Japan but also in Asia (APAC including China, Hong Kong, Taiwan, Singapore, Malaysia, India, Korea, and Thailand).
  • Relationships with domestic pharmaceutical companies cultivated through contracts*1 with 30 pharmaceutical and biotech companies, including 13 of the world's top 15*2 pharmaceutical companies.
*1 Within our group
*2 「Projecting the top 20 Big Pharma firms of FY2024」,DRUG Discovery & Development    https://www.drugdiscoverytrends.com/
 
 
【Achievements】
  • Track record of project support in a wide range of therapeutic areas
    • Oncology
    • Rare Diseases
    • CNS Diseases
    • Infectious Diseases
    • Orthopedics
    • Endocrinology / Metabolic Diseases
    • Pediatrics etc.
  • Contracts with more than 100 clinical trial sites, including national university hospitals.
  • An established network of more than 200 of our registered nurses to provide home nursing services covering the entire country.
  • Comprehensive agreements signed with 9 global DCT service vendors.
 
Future Outlook
 DCT Japan will promote the further spread and development of DCT based on the platform we have built and the results achieved to date. We will continue to expand the possibilities for new clinical trials in cooperation with pharmaceutical companies and healthcare professionals in order to provide more opportunities for patients to participate in clinical trials.
 
 
About DCT:
DCT (Decentralized Clinical Trial) is a clinical trial that does not rely on visits to medical sites by utilizing IoT such as wearable devices, online medical care and home nursing care by nurses. This reduces the burden of patients due to their health status and physical distance from the clinical trial site and contributes to improved patient enrollment and lower trial costs.
 
About DCT Japan： 
DCT Japan Inc. was established in February 2022 as part of the Integrity Healthcare Group and is the first company in Japan specializing in decentralized clinical trials. The company provides comprehensive solutions related to DCT, focusing on home nursing, IT solutions such as online medical care systems, as well as recruiting patients through the establishment of a network of satellite sites.  https://dctj.co.jp/
 
 
For related inquiries, please contact
DCT Japan Inc.
Public Relations: pr＠dctj.co.jp

関連記事